ArticleRegenerative biomaterials2026
Sustained
Article in Regenerative biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic diabetic wounds persist because inflammation, oxidative stress and impaired angiogenesis create a hostile microenvironment. We developed an exosome-functionalized, aligned poly(lactic-co-glycolic acid)/gelatin electrospun dressing (EE@PG) that serves as a local depot for sustained delivery of endothelial progenitor cell-derived exosomes. EE@PG scavenged hydroxyl and superoxide radicals and showed enzyme-mimetic antioxidant activity. Under lipopolysaccharide stimulation, EE@PG lowered intracellular reactive oxygen species, restored mitochondrial membrane potential and promoted RAW264.7 macrophage polarization toward a reparative phenotype while improving human umbilical vein endothelial cell viability and tube formation. In a splinted full-thickness STZ-induced diabetic rat model, EE@PG accelerated wound closure, enhanced re-epithelialization and collagen remodeling and increased neovascularization and vessel maturation. Transcriptomic analysis supported a shift toward immune resolution and tissue repair programs. Hemolysis, serum chemistry and organ histology indicated favorable biosafety. This work highlights a generalizable drug-delivering nanofibrous dressing that couples sustained exosome signaling with aligned structural cues for chronic wound management in clinically relevant settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.